Overview

A Study to Evaluate the Effect of Dapagliflozin on Blood Glucose Level and Renal Safety in Patients With Type 2 Diabetes

Status:
Completed
Trial end date:
2017-11-07
Target enrollment:
Participant gender:
Summary
The purpose of this clinical research study is to determine whether dapagliflozin can improve (decrease) blood glucose values in patients with Type 2 diabetes and moderate renal impairment.This study will be conducted at approximately 100 centres from countries across North America and European regions. It is planned to randomize a total of 302 patients.
Phase:
Phase 3
Details
Lead Sponsor:
AstraZeneca
Treatments:
Dapagliflozin